New Delhi: The Drugs Controller General of India (DCGI), the national regulator, after careful examination, has accepted the recommendation of Subject Expert Committee (SEC) and accorded permission to conduct the Phase II/III clinical trial of Covaxin (COVID vaccine) in the age group of 2 to 18 years, to its manufacturer Bharat Biotech Ltd.
The Hyderabad- based Pharmaceutical Company had proposed to carry out a Phase- II/III clinical trial of Covaxin in the age group of 2 to 18 years. The trial will be conducted in 525 healthy volunteers.
